

Research Paper

Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis

Yan Jiang¹, Chan Xiang², Fan Zhong¹, Yang Zhang¹, Liyan Wang^{2,3}, Yuanyuan Zhao^{2,3}, Jiucun Wang³, Chen Ding³, Li Jin³, Fuchu He^{1,4}✉ and Haijian Wang^{2,3}✉

1. Shanghai Fifth People's Hospital of Fudan University, Shanghai Key Laboratory of Medical Epigenetics, Ministry of Science and Technology International Co-Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
2. Center for Medical Research and Innovation, Shanghai Pudong Hospital and Pudong Medical Center, Shanghai Medical College, Fudan University, Shanghai, China.
3. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, Ministry of Education Key Laboratory of Contemporary Anthropology and Department of Anthropology and Human Genetics, School of Life Sciences, Fudan University, Shanghai, China.
4. State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences, Beijing Institute of Lifeomics, Beijing, China.

✉ Corresponding authors: Haijianwang Wang, PhD. Shanghai Pudong Hospital and School of Life Sciences, Fudan University, Shanghai, China. Tel.: +86 21 31246678, E-mail: haijianwang@fudan.edu.cn; Fuchu He, Institutes of Biomedical Sciences, Fudan University, Shanghai, China. Tel.: +86 21 54237158, E-mail: hefc@nic.bmi.ac.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Received: 2020.03.26; Accepted: 2020.09.09; Published: 2021.01.01

Abstract

Rationale: As the central hallmark of liver fibrosis, transdifferentiation of hepatic stellate cells (HSCs), the predominant contributor to fibrogenic hepatic myofibroblast responsible for extracellular matrix (ECM) deposition, is characterized with transcriptional and epigenetic remodeling. We aimed to characterize the roles of H3K27 methyltransferase EZH2 and demethylase JMJD3 and identify their effective pathways and novel target genes in HSCs activation and liver fibrosis.

Methods: In primary HSCs, we analyzed effects of pharmacological inhibitions and genetic manipulations of EZH2 and JMJD3 on HSCs activation. In HSCs cell lines, we evaluated effects of EZH2 inhibition by DZNep on proliferation, cell cycling, senescence and apoptosis. In CCl₄ and BDL murine models of liver fibrosis, we assessed *in vivo* effects of DZNep administration and *Ezh2* silencing. We profiled rat primary HSCs transcriptomes with RNA-seq, screened the pathways and genes associated with DZNep treatment, analyzed EZH2 and JMJD3 regulation towards target genes by ChIP-qPCR.

Results: EZH2 inhibition by DZNep resulted in retarded growth, lowered cell viability, cell cycle arrest in S and G₂ phases, strengthened senescence, and enhanced apoptosis of HSCs, decreased hepatic collagen deposition and rescued the elevated serum ALT and AST activities of diseased mice, and downregulated cellular and hepatic expressions of H3K27me₃, EZH2, α -SMA and COL1A. *Ezh2* silencing by RNA interference *in vitro* and *in vivo* showed similar effects. JMJD3 inhibition by GSK-J4 and overexpression of wild-type but not mutant *Jmjd3* enhanced or repressed HSCs activation respectively. EZH2 inhibition by DZNep transcriptionally inactivated TGF- β 1 pathway, cell cycle pathways and vast ECM components in primary HSCs. EZH2 inhibition decreased H3K27me₃ recruitment at target genes encoding TGF- β 1 pseudoreceptor BAMBI, anti-inflammatory cytokine IL10 and cell cycle regulators CDKN1A, GADD45A and GADD45B, and increased their expressions, while *Jmjd3* overexpression manifested alike effects.

Conclusions: EZH2 and JMJD3 antagonistically modulate HSCs activation. The therapeutic effects of DZNep as epigenetic drug in liver fibrosis are associated with the regulation of EZH2 towards direct target genes encoding TGF- β 1 pseudoreceptor BAMBI, anti-inflammatory cytokine IL10 and cell cycle regulators CDKN1A, GADD45A and GADD45B, which are also regulated by JMJD3. Our present study provides new mechanistic insight into the epigenetic modulation of EZH2 and JMJD3 in HSCs biology and hepatic fibrogenesis.

Key words: liver fibrosis, HSC, EZH2, JMJD3, epigenetics

Introduction

Hepatic fibrosis is the common feature of most chronic liver disease and its progression toward cirrhosis is the major cause of liver-related morbidity and mortality. A central hallmark of liver fibrosis is the uncontrolled activation of hepatic stellate cells (HSCs), the predominant contributor to fibrogenic hepatic myofibroblast during liver injury [1-3]. HSCs transdifferentiation is associated with dramatic morphological and biological changes including lipid droplets disappearing, enhanced proliferation, excessive collagen deposition and extracellular matrix (ECM) accumulation. Transforming growth factor β 1 (TGF- β 1) is the most potent profibrogenic cytokine that promotes HSCs transdifferentiation through activating the canonical TGF- β /SMAD signaling pathway. Activated HSCs could undergo proliferation, senescence, apoptosis and reversion of transdifferentiation [4]. Dysregulation and dysfunction of the underlying pathways and genes for phenotypic transition and fate-decision of HSCs are involved in liver fibrogenesis, which could be at least partly ascribed to their epigenetic alterations including DNA methylation, histone acetylation and methylation, microRNAs and long non-coding RNAs [5, 6].

Methylations of histone H3 on lysine 4, lysine 9 and lysine 27 are dynamic and important epigenetic modifications during HSCs activation. Trimethylated histone H3 on lysine 4 (H3K4me3) correlates with genes activation, while H3K9me2/3 and H3K27me2/3 usually lead to gene repression [7]. Methyl-CpG binding protein 2 (MeCP2) promotes H3K9 methylation and recruits transcriptional repressor at *PPAR γ* gene, a pivotal negative regulator for HSCs transdifferentiation [8, 9]. H3K27me3 is executed by polycomb repressive complex (PRC) including enhancer of zeste 2 (EZH2) and suppressor of zeste 12 (SUZ12) as core components. EZH2 is upregulated in activated HSCs, its genetic and pharmacological disruptions phenotypically reduce fibrogenic characteristics of myofibroblasts and attenuate liver fibrogenesis [8]. EZH2 inhibition by 3-Deazaneplanocin A (DZNep) has been proposed a proof-of-concept for epigenetic therapy of liver fibrosis, which is one of the most potent S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors with broad effects on histone lysine methyltransferase activities, and a widely used H3K27me3 methyltransferase inhibitor of EZH2 for anti-cancer therapeutic development [10]. EZH2 is also overexpressed in renal fibrosis [11-13], idiopathic pulmonary fibrosis (IPF) [14, 15], and systemic sclerosis (SSc) [16], a prototypical idiopathic fibrotic

disease, its inhibition by DZNep attenuates these fibrotic conditions. GSK126, a highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, was also reported to show therapeutic effects in experimental and clinical settings including lymphoma with EZH2-activating mutations [17] and atrial fibrosis [18]. Mechanistically, some target genes of EZH2 and their functions in liver fibrosis has been characterized. For example, *PPAR γ* silencing in HSCs activation is partly ascribed to strengthened H3K27me3 at *PPAR γ* chromatin mediated by EZH2 [8, 19]. However, the functional roles and other novel effective target genes of EZH2 remain to be further elucidated.

Histone methylation is dynamically regulated by methyltransferase and demethylase. We previously reported that the jumonji domain containing protein 1A (JMJD1A), also known as lysine demethylase 3A (KDM3A), modulates HSCs activation and liver fibrosis through demethylating H3K9me2 at *PPAR γ* promoter and positively regulating its expression [20]. JMJD2D, or KDM4D, was recently reported as a remarkable overexpressed H3K9me2/3 demethylase during HSCs activation, it epigenetically facilitates TLR4 gene transcription and thus activates TLR4/NF- κ B signaling pathways, promotes HSCs activation and hepatic fibrosis progression [21]. Removal of H3K27me2/3 methylation marks is specifically mediated by the JmjC domain-containing histone demethylases JMJD3 (KDM6B) and UTX (Ubiquitously transcribed Tetratricopeptide repeat on chromosome X) (KDM6A) [22]. JMJD3 is involved in cellular processes including differentiation, proliferation, senescence, and apoptosis, and thus is implicated in development and diseases [23]. JMJD3, UTX and EZH2 regulate hepatic plasticity inducing retro-differentiation and proliferation of hepatocytes [24]. In the setting of SSc, JMJD3, but not UTX, is overexpressed in SSc and murine models of skin fibrosis as well as in cultured fibroblasts, modulates fibroblast activation by regulating H2K27me3 content at *FRA2* gene promoter, which encodes the AP1 transcription factor that regulates ECM production. JMJD3 inhibition by GSK-J4, a specific inhibitor of H3K27me3 demethylase [25], inhibits fibroblast activation and ameliorates experimental fibrosis [26]. A recent report also demonstrated that JMJD3 plays direct roles in the pro-fibrotic cardiac fibroblast phenotype and its selective inhibition attenuates cardiac fibrosis [27]. But the biological significance and pathological relevance of JMJD3 in HSCs and liver fibrosis is yet unknown.

In the present study, we found that EZH2 and JMJD3 coordinately regulate HSCs activation, pharmacological and genetic abrogation of EZH2

ameliorates liver fibrosis in murine models. Using RNA-seq, we profiled the differential transcriptomes of primary HSCs associated with EZH2 inhibition, and mechanistically identified critical genes involved in liver fibrosis as novel direct targets under the epigenetic regulations of EZH2 and JMJD3, including the TGF- β 1 pseudoreceptor BAMBI gene.

Results

EZH2 and JMJD3 regulate HSCs activation

We first isolated rat primary HSCs, monitored culture-induced HSCs activation, and analyzed proteins expressions of EZH2, JMJD3, UTX and H3K27me2/3 (Figure 1A). EZH2 expression moderately increased during HSC activation, while JMJD3 was positively expressed in quiescent HSCs but was rapidly silenced and almost undetectable in activated HSCs. The expression of UTX in primary and activating HSCs was undetectable, suggesting possible redundancy in HSCs biology for the two H3K27me2/3 demethylases. In public transcriptome datasets cross human tissues [28], UTX transcript level in liver is relatively low, and a recent study also showed that UTX is deregulated during hepatic differentiation [24]. In line with previous finding that H3K27me2 is sharply silenced and H3K27me3 is

clearly increased in activated rat primary HSCs as compared with quiescent HSCs [7], we observed modest reduction in the pooled H3K27me2/3 level during HSCs activation. In multiple hepatic cell types including human (LX-2) and mouse (JS1) HSCs, we found ubiquitous and relatively high expression of EZH2 but the expression of JMJD3 was almost undetectable (Figure S1A). It has been also reported that rat *Ezh2* transcription is induced both in cultured myofibroblasts and in HSCs that are trans-differentiating *in vivo* in response to BDL and CCl₄ injury, while *Jmjd3* transcription is downregulated during HSCs activation [7, 8]. In the previously reported hepatic transcriptome expression data for 124 liver fibrosis patients (GSE84044 in NCBI GEO) [29], we found that transcriptions of *EZH2* ($r^2 = 0.26$, $P = 1.25E-09$) and other PRC2 components genes, *SUZ12*, *EED* and *RBBP4* were all positively correlated with sequential histological staging of fibrosis (Scheuer score, S) (Figure 1B), while no significant correlation was observed for *JMJD3* (data not shown). The expression pattern of EZH2 and JMJD3 during HSCs activation and liver fibrosis progression indicates that they might be involved in HSCs biology and have pathological relevance.




Figure 1. The association of EZH2 and JMJD3 expressions with HSC activation and liver fibrosis. (A) The expressions of EZH2, JMJD3, α -SMA, H3K27me2/3 and β -Actin as inner control during culture-induced activation of rat primary HSCs (0, 1, 3, 5, 7 days) was analyzed by Western blot. (B) In the gene arrays dataset for liver biopsy samples from 124 liver fibrosis patients (GSE84044, ref 29), linear regression was used to analyze the association of hepatic expression of PRC2 subunit genes (*EZH2*, *SUZ12*, *EED* and *RBBP4*) with sequential histological staging of fibrosis, Scheuer score, S, which is divided as S0 (stage 0, $n = 43$), S1 ($n = 20$), S2 ($n = 33$), S3 ($n = 18$) and S4 ($n = 10$). The box plot and fitting curve showed the association trend. The significance of correlation was expressed as r -squared values of regression and $P < 0.01$ was considered as statistical significance.




Figure 2. EZH2 and JMJD3 regulate HSC activation through modulating Tgfβ1 signaling pathway. Rat primary HSCs were cultured and treated with inhibitors of EZH2 (DZNep) or JMJD3 (GSK-J4), or transfected with siRNAs of *Ezh2*, or infected with adenovirus recombinant with *Jmjd3*. RNA-seq was conducted for HSCs treated with DZNep or DMSO as control. (A) HSCs growth and morphology were assessed in fifth day after administration, the magnification is 200×. (B-D) EZH2, JMJD3, α-SMA and COL1A expressions and H3K27 methylation level were determined by Western blot with β-ACTIN and Histone 3 as inner controls respectively. * $P < 0.05$. (E) Basing on the DEGs associated with DZNep treatment in HSCs, the upstream regulator analysis of IPA identified Tgfβ1 among the most significantly inhibited growth factors or cytokines. The top candidates are shown with overlap P value < 0.01 and |activation Z-score| > 2 . (F) The heatmap shows transcriptional value \log_{10}^{RPKM} for genes encoding effectors, activators and inhibitors of TGFβ1 signaling pathway. *Bambi* in the inhibitor panel was highlighted in red.

We therefore evaluated, in rat primary HSCs and mouse JS1 cell line, the effects of pharmacological inhibition and genetic manipulation of EZH2 and JMJD3 on morphological and biochemical phenotypes of HSCs activation. Treatment of primary HSCs with DZNep, or transient transfection with potent siRNAs for *Ezh2* silencing, resulted in more quiescent HSCs-phenotype and pronounced growth retardation (Figure 2A), remarkably weakened H3K27me2/3, and significantly downregulated α-SMA and COL1A (Figure 2B-C). These epigenetic and biochemical changes were also observed in primary HSCs with adenovirus-mediated stable overexpression of wild-type *Jmjd3*, but not of its demethylation-defective mutant (Figure 2D). Similarly, *Ezh2* silencing in JS1 cells with retrovirally-expressed shRNAs significantly weakened H3K27me2/3 and downregulated α-SMA and COL1A, while stable overexpression of wild-type *Ezh2*, but not of its methylation-defective mutant, significantly upregulated α-SMA and COL1A (Figure S1B-C). In contrast, treatment of primary HSCs with GSK-J4, an jumonji H3K27me3 demethylase inhibitor of JMJD3 [30], resulted in enhanced cell growth, morphological transition from quiescent HSCs to myofibroblast, reinforced H3K27me3, and

upregulated fibrotic markers (Figure 2A, C). These data suggest that EZH2 and JMJD3 regulate HSCs activation.

Because EZH2 is expressed in activated HSCs and its hepatic expression positively correlates with fibrosis staging, we thus focused on the phenotypic relevance of pharmacologic and genetic abrogation of EZH2 *in vitro* and *in vivo*. EZH2 inhibition by DZNep in mouse JS1 cells resulted in cell cycle arrest in S and G2 phases (Figure 3A), lowered cell viability (Figure 3B), increased cell senescence (in dose dependent mode) (Figure 3D), and higher percent of early apoptotic cells (Figure 3E-F). Similar effects on these cellular phenotypes of DZNep were also observed in human LX-2 cells (Figure S1D-F). Of note, DZNep treatment in rat primary HSCs, JS1 and LX-2 cells significantly lowered the transcriptional expression of cell proliferation marker protein Ki-67 coding gene *MKI67* (marker of proliferation Ki-67) (Figure 3C). On the other hand, treatment of JS1 cells with GSK126 also increased cell senescence but not in dose dependent fashion (Figure 3D). High dose (10 μM) GSK126 treatment in both JS1 (Figure 3A, E-F) and LX-2 (Figure S1E-F) significantly increased the percentages of the cells in G1 phase and of early

apoptosis cells. However, high dose (10 μM) GSK126 treatment sharply reduced the cell viabilities of JS1 (Figure 3B) and LX-2 (Figure S1D), suggesting possible cytotoxicity of GSK126 towards HSCs. These results suggest that EZH2 is one key epigenetic regulator for HSCs proliferation, senescence and apoptosis, its inhibition with DZNep could modulate these cellular phenotypes.

In order to uncover the underlying pathways and genes for broader effects of DZNep on HSCs phenotypes, we profiled the transcriptomes of rat primary HSCs treated with DZNep using RNA-seq. We identified 2,639 (806 upregulated and 1,833 downregulated) associated DEGs, the transcriptions of 43 candidates among them were also validated with RT-qPCR (Figure S2). Given that quiescent HSC is activated by extracellular mediators including cytokines and growth factors that trigger intracellular downstream effectors [4], we used IPA URA to investigate the effect of DZNep treatment on functionality of upstream regulators. For the observed DEGs, IPA identified Tgf β 1 and Tgf β 3, two

well-defined pivotal profibrogenic cytokines, among the most significantly inhibited upstream regulators with molecule type as growth factor or cytokine (Bonferroni corrected $P < 0.01$). 154 out of the 351 associated DEGs in knowledgebase have measurement direction consistent with Tgf β 1 inhibition ($P = 9.96\text{E-}30$, Z-score = -2.087), the majority (127) of which are downregulated activator or effector genes, while a few (27) are upregulated inhibitor genes (Figure 2E-F). Because EZH2 inhibition could supposedly release the repression of its direct target genes, we therefore emphasized on the upregulated inhibitor genes of Tgf β 1, and found that DZNep treatment resulted in significant upregulation of *Bambi* (bone morphogenetic protein and activin membrane bound inhibitor), the TGF- β 1 pseudo-receptor gene and the key negative regulator of TGF β signaling [31]. These data suggest that EZH2 inhibition by DZNep in HSCs could pervasively attenuate TGF- β /SMAD signaling pathway through, in part at least, modulating the expression of its regulators such BAMBI.




Figure 3. Cellular phenotypic effects of EZH2 inhibition with DZNep or GSK126 on HSCs cell cycling, proliferation, senescence and apoptosis. JS1 cells were administrated with DZNep, GSK126 or DMSO and subjected to analyses of cell cycle (A), cell growth (B-C), senescence (D) and apoptosis (E-F) with staining and flow cytometry. The transcriptional expression of cell proliferation marker MKI67 gene in rat primary HSC, human LX-2 and mouse JS cells were measured by RT-qPCR (C). Cell senescence was determined by measuring SA- β -Gal activity (D). The apoptotic cells were determined by Annexin-V-PI double staining (E) and FITC-dUTP staining by TUNEL apoptosis assay (F). The yellow frames in panel E present early apoptotic cells. Data were measured from triple independent experiments. * $P < 0.05$, ** $P < 0.01$.




Figure 4. DZNep treatment of HSCs disturbs the transcriptional expressions of cell cycle regulator genes. Rat primary HSCs were treated with DZNep or DMSO, their transcriptomes were compared with RNA-seq profiling. The pre-ranked gene list was subjected to bioinformatics analysis tool GSEA. Significant enrichment of gene sets related to regulation of cell cycle, DNA replication, cell division and ribosomal proteins were demonstrated (A-B). NES: normalized enrichment score, FDR: false discovery rate. (C) The heatmap shows expression values of genes involved in cell cycle regulation. *Mki67* as one well-defined cell proliferation marker in the cell cycle panel, *Cdkn1a*, *Gadd45a* and *Gadd45b* in the cell cycle inhibitor panel were highlighted.

To ascertain the thematic association of gene signature for DZNep treatment, we conducted functional enrichment analysis. Interestingly, key signaling pathways involved in cell cycle, DNA replication, mitotic cell cycle and spindle organization, and cytoplasmic ribosomal proteins were significantly inactivated (Figure 4A-B). Specifically, some positive regulators of cell cycle including cyclins, cyclin-dependent kinases and E2F transcription factors, and of mitosis were pervasively downregulated; while the key negative regulators of cell cycle, *Cdkn1a* (cyclin dependent kinase inhibitor 1A), *Gadd45a* (growth arrest and DNA damage inducible alpha) and *Gadd45b*, the target genes of p53 and primary inhibitors of G2/M transition) were upregulated (Figure 4C). These results indicate that DZNep-induced cycle arrest, proliferation inhibition and apoptosis of HSCs might be ascribed to the perturbed expression of cell cycle regulators such as CDKN1A and GADD45.

Pharmacological and genetic abrogation of EZH2 ameliorates liver fibrosis in vivo

To decipher the pathological relevance of EZH2 in hepatic fibrosis, we investigated *in vivo* phenotypes

of pharmacological inhibition and genetic knockdown of EZH2 in two murine models of liver fibrosis (CCl₄ and BDL). DZNep administration in diseased mice with CCl₄ significantly downregulated the expressions of EZH2 (mRNA, *P* = 0.041; protein, *P* = 0.0001) and H3K27me3 (*P* = 0.015) in liver (Figure 5A-C). We observed consistently downregulated hepatic transcriptional expression of fibrotic marker genes *a-Sma*, *Col1a1* and *Mmp2* in treatment mice (Figure 5C). The Masson staining results showed that collagen deposition was significantly reduced in DZNep-treatment panels of both CCl₄ (*P* = 0.019) and BDL (*P* = 0.083) mice (Figure 6A-B). Consistently, the IOD of positive α-SMA areas, the marker of *in-situ* activated HSCs, was also significantly decreased in treatment panel (*P* = 0.013 and 0.058 for CCl₄ and BDL models respectively) (Figure 6C-D). DZNep treatment also decrease the content of hydroxyproline in liver tissues and serum both in CCl₄ (*P* = 0.064 in liver tissues and *P* = 0.089 in serum) and BDL models (*P* values being 0.086 and 0.011 respectively) (Figure 6E). Furthermore, we also investigated the effect of *Ezh2* silencing *in vivo* on liver fibrogenesis. Based on our recently proposed amiRNA strategy [32], we designed the lentivirally expressed and HSC specific *GFAP*

gene promoter driven amiRNA system (amiR-*Ezh2*) for targeted *Ezh2* silencing (Figure 7A). The JS1 cells infected with this lentiviral-amiR-*Ezh2* showed efficient *Ezh2* silencing and significant down-regulation of COL1A and α -SMA (Figure 7B). In CCl₄ mice, hepatic delivery and transduction of recombinant lentivirus particles through tail vein injection, resulted in pronounced reductions in collagens deposition ($P = 0.038$) and α -SMA expression *in-situ* ($P = 0.095$) in fibrotic tissue (Figure 7C). Consistent with the therapeutic effect of DZNep *in vivo*, in the transcriptomic analysis of rat primary HSCs treated with DZNep, we found striking inactivation of ECM related gene set for the GO category “extracellular matrix” by GSEA (Figure 5D). A variety of ECM components, provisional ECM components, fibrotic ECM components, and the synthase genes for hyaluronan, a ubiquitous component of different stages of ECM considered as a biomarker and driving factor for fibrosis [33] (Figure 5E). Collectively, the *in vitro* and *in vivo* data suggest

that EZH2 inhibition by DZNep attenuates TGF- β /SMAD signaling in HSCs, inhibits HSCs activation, mitigates hepatic ECM accumulation and eventually ameliorates liver fibrosis.

EZH2 inhibition by DZNep alleviates liver injury and epigenetically up-regulates *Il10*

HSC is not only passive target of pro-fibrogenic factors but also central modulator of hepatic inflammation by secreting cytokines, which is profoundly linked to liver injury and fibrosis [34]. In the above *in vivo* study, DZNep administration significantly ameliorated the experimentally-induced elevation in activities of ALT ($P = 0.0004$ and 0.046) and AST ($P = 0.09$ and 0.059) in both CCl₄ and BDL mice, which serve as surrogates of hepatocellular damage (Figure 8A-B). Consistently, DZNep treatment of rat primary HSCs was associated with overall downregulation of *Il17b*, *Il17rb*, *Il17d* and *Il17re* genes (Figure 8C), which code components of IL17 signaling that not only directly induces collagen type I production in HSCs, but also is involved in promoting liver damage and fibrosis resulting from




Figure 5. DZNep treatment results in reduced hepatic expressions of fibrotic marker genes in mice with CCl₄-induced liver fibrosis and prevalent downregulation of ECM component genes in HSCs. Hepatic expressions of H3K27me3, Histone3, EZH2 and β -Actin in CCl₄ mice with DZNep or DMSO treatment were determined by Western blot (A-B). Hepatic transcriptions of *Ezh2*, α -Sma, *Col1a*, *Mmp2* and β -Actin were determined by RT-qPCR. The pre-ranked gene list for transcriptomic profiling of rat primary HSCs treated with DZNep or DMSO was subjected to GSEA, ECM genes were significantly enriched (C). The heatmap shows transcriptional changes of various ECM component genes (D). Statistical significance was determined with Student’s t-test in independent samples.

inflammasome activation [35, 36]. Particularly notable, DZNep treatment of HSCs resulted in significant upregulation of *Il10*, a well-defined anti-inflammatory cytokine [37-39], and remarkable downregulation of *Il11*, a putative pro-fibrogenic cytokine [40]. In accordance, DZNep treatment of BDL mice correlated with elevated and declined serum concentrations of IL10 ($P = 0.088$) and IL11 ($P = 0.005$) respectively (Figure 8F). Mechanistically, DZNep treatment in rat primary HSCs remarkably decreased H3K27me3 enrichment at *Il10* gene body (Figure 8G), and thereby significantly increased its transcript and protein expressions (Figure 8D-E). However, although consistent with the significant

reduction in the mRNA and protein expression of IL11 gene (Figure 8D-E), the sharply strengthened occupancy of H3K27me3 at *Il11* gene body (Figure 8G) associated with DZNep treatment, is apparently contrary to the inhibitory effect of DZNep towards the H3K27 methyltransferase activity of EZH2. This discrepancy could be possibly ascribed to the broad effects of DZNep on histone lysine methyltransferase activities, suggests the complex H3K27me3 homeostasis and epigenetic regulation on IL11 gene expression. These data suggest that EZH2 inhibition by DZNep alleviates experimental liver injury partial through epigenetically regulating *Il10*.




Figure 6. DZNep treatment ameliorates hepatic fibrogenesis in mice. The effect of DZNep on hepatic fibrosis induced by CCl₄ (A) or BDL (B) was measured by Masson's trichrome staining. The effect of DZNep on HSCs activation *in vivo* was measured by immunohistochemistry of α-SMA (C-D). The effect of DZNep on the collagen level was measured by concentration of hydroxyproline in liver tissues and serum (E).




Figure 7. HSC-specific *Ezh2* silencing *in vivo* ameliorated liver fibrosis. **(A)** Construction of amiRNA vector for *Ezh2* silencing. The amiRNA consisted of miR-30a backbone as structural scaffold and two concatenated pre-miR30-shRNA cassettes embedding valid interfering shRNA (amiR-Ezh2) or negative control shRNA (amiR-NC) as cargos. Based on lentiviral microRNA expressional vector, amiRNA was inserted into the cloning site located in EGFP intron, the original CMV promoter was substituted with human GFAP promoter. **(B)** *Ezh2* silencing in JS1 cells was achieved by infection of lentiviral-amiR-Ezh2, expressions of EZH2, COL1A, α -SMA and β -ACTIN were determined by Western blot. **(C)** In CCl₄ mice, lentivirally expressed amiRNA was transduced into the liver through tail-vein injection, therapeutic effects of amiRNA-based HSC-specific *Ezh2* silencing was analyzed by measuring collagens deposition with Masson's trichrome staining and α -SMA expression with immunohistochemistry.

EZH2 and JMJD3 regulate *Bambi*, *Cdkn1a* and *Gadd45* genes in HSCs

Given that H3K27me₃ is usually silencing epigenetic mark that could be coordinately regulated by EZH2 and JMJD3, we hypothesized that some upregulated DEGs associated with DZNep treatment of HSCs might be common targets of EZH2 and JMJD3, which could be exemplified by *Bambi*, *Cdkn1a*, *Gadd45a* and *Gadd45b* that are involved in regulation of HSCs activation and proliferation. Indeed, DZNep-mediated EZH2 inhibition and adenovirus-mediated *Jmjd3* overexpression in rat primary HSCs both consistently decreased H3K27me₃ enrichment at promoters and gene bodies of *Bambi*, *Cdkn1a*, *Gadd45a* and *Gadd45b*, increased their transcriptional expression both at early (3 days) and late (6 days) stage of HSCs activation (Figure 9A-D). We also observed substantial increase in protein expression for BAMBL, CDKN1A and GADD45B in HSCs with DZNep treatment or with overexpression of wild-type but not mutant *Jmjd3* (Figure 9E-F). Furthermore, DZNep treatment in CCl₄ and BDL mice correlated with consistently upregulated hepatic transcription of *Bambi* ($P = 0.038$ and 0.079) and *Cdkn1a* ($P = 0.156$ and 0.018) (Figure 9G-H). The *in vitro* and *in vivo* data

collectively suggest that EZH2 and JMJD3 coordinately modulate HSCs activation and liver fibrosis through, at least in part, epigenetically regulating *Bambi*, *Cdkn1a*, *Gadd45a* and *Gadd45b*.

Discussion

HSCs activation is the core event of hepatic fibrogenesis. The phenotypic transition of quiescent HSCs (qHSCs) to myofibroblasts is underpinned by transcriptional remodeling, which could be epigenetically regulated by histone modifications. In this study, we characterized divergent expressions and antagonistic functions of histone H3K27 methylase EZH2 and demethylase JMJD3 in HSCs activation and liver fibrosis. We showed that EZH2 and JMJD3 contrastingly regulated HSCs activation, EZH2 inhibition by DZNep or its silencing by siRNA repressed HSCs activation and proliferation, while *Jmjd3* overexpression also achieved these effects. Furthermore, DZNep-treatment or HSC-targeted *Ezh2* silencing by amiRNA in diseased mice ameliorated experimental liver fibrosis. To our best knowledge, this study is among the few that have investigated the roles of both methyltransferase and demethylase for histone epigenetic modification in liver fibrosis.




Figure 8. DZNep treatment confers protection against liver injury and correlates with IL10 upregulation and IL11 downregulation. Serum ALT and AST activities of CCl₄ (A) and BDL mice (B) treated with DZNep or DMSO was measured by biochemistry analyzer. The heatmap shows transcription changes of interleukin related genes in rat primary HSCs associated with DZNep treatment (C), among which transcription expressions of *Il10*, *Il11*, *Il1a*, and *Il10rb* were validated by RT-qPCR (D), and protein expressions of IL10 and IL11 were measured by Western blot (E). Serum concentration of IL10 and IL11 of BDL mice and controls were measured by ELISA (F). Enrichments of H3K27me3 at gene bodies of *Il10* and *Il11* in rat primary HSCs treated with DZNep or DMSO were determined by ChIP-qPCR (G). Statistical significance was determined by Student's t-test. * $P < 0.05$, ** $P < 0.01$.

One of our novel findings is that EZH2 and JMJD3 regulate HSCs activation partially at least through epigenetically modulating the expression of *BAMBI*, the key negative regulator of TGF β signaling. *BAMBI* is a TGF β superfamily type I receptor that lacks intracellular kinase domain and therefore blocks the signal transduction [31]. *BAMBI* also forms a ternary complex with SMAD7 and TGF β type I receptor, impairs SMAD3 activation and thus inhibits signal transduction [41]. *BAMBI* is expressed at high levels in quiescent HSCs but at low levels in *in vivo*-activated HSCs isolated from CCl₄ and BDL mice; its overexpression prevents HSCs activation, whereas its dominant negative form leads to strongly sensitized HSCs to TGF β [42]. Hepatic *BAMBI* expression in liver fibrosis patients with advanced stage is lower as compared to those with mild or no fibrosis [43]. In murine liver fibrosis, intestinal bacterial endotoxin lipopolysaccharide and dietary cholesterol stimulate Toll-like receptor 4, induce occupancy of NF- κ Bp50 and HDAC1 on *Bambi*

promoter, and downregulate its expression in HSCs, leading to enhanced TGF β signaling and increased HSCs activation and hepatic fibrosis [42, 44, 45]. Interestingly, as a key mediator in TGF- β 1-driven HSCs activation, EZH2 itself is upregulated in HSCs treated with TGF- β 1 [46]. In fibroblasts from human lung affected with idiopathic pulmonary fibrosis, TGF- β 1 treatment significantly increases the association of EZH2 to its target gene and reinforces epigenetic repression [47]. It is therefore plausible that DZNep treatment of HSCs could disrupt EZH2-mediated epigenetic repression of *BAMBI*, then strengthen the inhibition of TGF- β 1 signaling, and thereby result in reduced EZH2 expression. Indeed, we here and other groups have consistently observed that DZNep not only inhibits EZH2 activity but also decreases its expression in cells including HSCs, SSc dermal fibroblasts, lung fibroblasts, renal fibroblasts, and in fibrotic tissues from diseased animals including liver, lung and kidney [11, 13, 15, 16, 48].




Figure 9. EZH2 and JMJD3 regulate *Bambi*, *Cdkn1a*, *Gadd45a* and *Gadd45b*. Primary rat HSCs were treated with DZNep or infected with adenovirus-*Jmjd3* or their controls respectively. The effects of DZNep on H3K27me3 (A) or *Jmjd3* overexpression on H3K27me2/me3 (B) enrichments at target genes were determined by ChIP-qPCR. The 5' endpoints of PCR products are positioned as upstream (-) or downstream (+) from transcription start sites. The effect of DZNep treatment or *Jmjd3* overexpression on transcript and protein products of target genes were determined by RT-qPCR (C-D) and Western blot (E-F) respectively. β -Actin was used as internal control. Hepatic transcriptions of *Bambi* and *Cdkn1a* in CCl₄ (G) and BDL (H) mice were determined by RT-qPCR. * $P < 0.05$, ** $P < 0.01$.

The epigenetic modulation of TGF β signaling by EZH2 could be evidenced by the observations that DZNep treatment of HSCs resulted in prevalent reduction in ECM expression, whose remodeling and turnover are among the key characteristics of activated HSCs, and pervasive downregulation of its downstream effector genes including *Il11*. *Il11* upregulation is the dominant transcriptional response of primary cardiac fibroblasts to TGF β 1 exposure, fibroblast-specific *Il11* transgene expression or IL11 injection in mice causes heart and kidney fibrosis, whereas its genetic abrogation protects against disease [40]. *Il11* is transcriptionally regulated by TGF β 1 and IL1A in pulmonary fibroblasts and is highly upregulated in fibroblasts from patients with systemic sclerosis [49, 50]. Interestingly, we here report that *Il11* gene and its upstream regulator *Il1a*

gene were highly transcribed in cultured primary HSCs, DZNep-treatment significantly down-regulated *Il11* but did not affect *Il1a* expression (Figure 8C-D). Furthermore, in BDL mice, IL11 serum concentration was higher than SHAM control, but the experimentally induced elevation was effectively rescued after DZNep-treatment (Figure 8F). These data highlight that EZH2 inhibition by DZNep could diminish IL11 expression via targeting its upstream TGF β signaling, suggesting IL11 as a crucial profibrotic factor in the liver beyond cardiovascular and pulmonary systems.

In addition to acting as the predominant contributor to hepatic myofibroblasts, HSCs also regulate liver inflammation and exert hepatoprotection through their own gene expression and interplay with other liver cells [51]. Notably, in CCl₄

and BDL mice, we found that DZNep administration alleviated liver injury and correlated with altered expression of interleukin genes in HSCs that play roles in inflammatory responses and fibrogenesis, among which, *Il10* was further characterized as direct target of EZH2. In the liver, IL10 and its receptor IL10R α can be produced by HSCs and Kupffer cells. Their binding activates IL10R α -STAT3 pathway, induces IL10 response genes expression, and thereby modulates liver inflammation and fibrosis. IL10 is very low in primary HSCs but is significantly increased during activation [38]. *Il10* knockout mice or treatment with anti-IL10 antibody is associated with severe fibrosis [37], while its transgenic expression in liver alleviates fibrosis [52]. In humans, IL10 treatment normalizes serum ALT level, improves liver histology and reduces liver fibrosis in patients with chronic hepatitis C [53], and the high IL10 production haplotype of its gene promoter is associated with reduced susceptibility to liver cirrhosis [54]. Thus the protective role of DZNep against liver injury might be associated with the epigenetic regulation of *Il10* by EZH2. Interestingly, it was reported that GSK-J4 administration of macrophages and natural killer cells reduce IL10 expression [25, 55], raising the possibility that *Il10* may be among the common target genes regulated by both EZH2 and JMJD3.

Another notable aspect of this study is that EZH2 and JMJD3 epigenetically modulate HSCs phenotypes through regulating *CDKN1A* and *GADD45*. As a potent cyclin-dependent kinase inhibitor, *CDKN1A*, also known as p21, regulates cell progression, inhibits proliferation and induces senescence of HSCs, which facilitates the resolution of liver fibrosis [56, 57]. *CDKN1A* polymorphisms that are associated with decreased p21 expression predispose to liver fibrosis and idiopathic pulmonary fibrosis [58, 59]. *GADD45A* and *GADD45B* are members of the growth arrest and DNA damage-inducible 45 families that play key roles in growth suppression, DNA repair and apoptosis. Hepatic expression of *GADD45A* is suppressed in CCl₄ mice, while its overexpression in HSCs inhibits expression of ECM proteins and α -SMA [60]. *Gadd45a*-null mice with nonalcoholic steatohepatitis show more severe hepatic fibrosis and inflammation [61]. The increased expressions of *CDKN1A* and *GADD45* in HSCs are associated with inhibited HSCs activation and ameliorated liver fibrosis in rats treated with PPAR γ agonist or histone deacetylase inhibitor [62, 63]. It was reported that EZH2 regulates cellular senescence through epigenetically repressing the expression of p21 in cancer cells [64]. In alike manner, JMJD3 can epigenetically upregulate *Gadd45a*, promote cell senescence and thus inhibit iPSCs

reprogramming [65]. The present study also adds *Cdkn1a* and *Gadd45* genes to the epigenetic regulatory network of EZH2 and JMJD3 in HSCs biology and hepatic fibrogenesis.

Due to the established oncogenic and pro-fibrotic functions of EZH2, its pharmacologic intervention with inhibitors including DZNep has been proposed as promising therapy for neoplastic and fibrotic disorders. EZH2 inhibition by DZNep as an epigenetic drug shows anti-proliferative, pro-apoptotic effects in cancer cells [66], and attenuates TGF β -dependent HSCs activation [46]. A few responsive signaling pathways and target genes have been shown to be associated with these therapeutic effects in animals [11, 13, 16, 48, 66]. However, DZNep acts as a broad specificity inhibitor of histone methyltransferase that suppresses both repressive and active histone methylation marks [10, 67]. In certain circumstances, EZH2 also has non-canonical non-methyltransferase functions that affect transcription and translation [68, 69]. Thus we should cautiously point out that the gene signature of HSCs associated with DZNep treatment may be affected by these potential confounding factors. Indeed, in transcriptomic profiling of cells and tissues from experimentally diseased animals with DZNep treatment, we and other groups observed strikingly differential percent of DEGs were upregulated [10, 12]. In this study, we also measured the *in vitro* effects of GSK126, a highly selective inhibitor of EZH2 methyltransferase activity, on the cellular phenotypes of HSCs. The immediate sharp reduction in cell viability associated with GSK126 treatment of mouse JS1 or human LX-2 cells suggests its cytotoxicity towards HSCs. We here clearly uncover a few important fibrosis related genes, *Bambi*, *Cdkn1a*, *Gadd45a*, *Gadd45b* and *Il10*, as direct epigenetic targets for the H3K27 methyltransferase activity of EZH2, their reactivation by DZNep treatment could, in part at least, account for the beneficial effects of DZNep against HSCs activation and liver fibrogenesis. Given that these target genes encode pivotal regulators for TGF β signaling, cellular apoptosis and senescence, their epigenetic regulation by EZH2 may have relevance in fibrogenesis of other organs beyond liver, which shed more light into the underlying mechanisms of DZNep therapy against tissue fibrogenesis and tumorigenesis.

Compared with the well-defined oncogenic and pro-fibrotic functions of EZH2, JMJD3 is a double-edged sword with complex and somehow opposite functions in different context of disease, tissue and cell type. Accumulating evidence have shown that JMJD3 plays pro-inflammatory or anti-inflammatory in immune diseases, and carcinogenic or tumor

suppressive roles in various types of cancer, which is associated with the histone demethylase activity-dependent epigenetic regulation and its noncanonical noncatalytic functions [23, 65]. As JMJD3 stimulates a wide range of genes implicated in inflammation, immunity, development, senescence and carcinogenesis, its expression in normal conditions is usually in low level in the organization, just as its undetectable expression in the tested hepatic cell lines in this study, its activation is an important host response against environmental and cellular stress. As a JMJD3 specific small-molecular inhibitor, GSK-4 has been used in selective pharmacological intervention of JMJD3 in a few mouse disease models. In line with this scenario, the upregulation and pro-fibrotic role of JMJD3 in SSc, cardiac fibrosis and chronic cystitis induced bladder fibrosis have been recently reported [26, 27, 70]. However, we here documented that JMJD3 was relatively highly expressed in rat primary HSCs but was rapidly silenced during their activation. The cellular phenotype of GSK-4 treatment and JMJD3 ectopic expression suggest it as a pivotal negative regulator for HSC activation, which could be ascribed to, in part at least, as discussed above, its epigenetic regulation towards target genes including *Bambi*, *Cdkn1a*, *Gadd45a* and *Gadd45b* that regulate HSCs activation, apoptosis and senescence. Although we did not find clear correlation between JMJD3 expression and fibrosis staging in the cohort of liver fibrosis patients [29], a recent study showed that JMJD3 promotes hepatic autophagy by epigenetically upregulating global autophagy-network genes, the hepatic expression of JMJD3 and these key autophagy genes was substantially decreased in non-alcoholic fatty liver disease (NAFLD) patients (both simple steatosis and advanced NASH-fibrosis patients) as compared to normal subjects [71]. We should acknowledge that this study has limitations and only provided, for the first time, *in vitro* evidence to support JMJD3 as key negative regulator against HSCs activation, HSCs-targeted *Jmjd3* transgene *in vivo* investigation in mouse models with adeno-associated viral vector, which is enabled to host large gene sequences like *Jmjd3* [72], is highly warranted to further elucidate the function of JMJD3 in liver fibrosis and its possible translational application for epigenetic gene therapy.

In summary, through pharmacological and genetic manipulations in HSCs and mouse liver fibrosis models and transcriptomic profiling of HSCs, we demonstrate that H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate *Bambi*, *Cdkn1a*, *Gadd45a* and *Gadd45b* genes in HSCs, which is functionally associated with the antagonistic roles of EZH2 and JMJD3 in HSCs activation, and with the

anti-proliferative, pro-apoptotic and anti-fibrotic benefits of EZH2 inhibitor DZNep treatment in both HSCs and mice. This study thus provides new mechanistic insight into the epigenetic modulation of EZH2 and JMJD3 in HSCs biology and hepatic fibrogenesis.

Methods

Cell lines, plasmids and experimental animals

Mouse HSC cell line JS1 was provided by Professor Jinsheng Guo at the Division of Digestive Diseases, Zhongshan Hospital of Fudan University. Human HSC cell line LX-2 was provided by professor Lieming Xu at Shanghai University of Traditional Chinese Medicine. The JS1 and LX-2 HSC cell lines were originally established by the providers respectively, and had been ascertained for identity with short tandem repeat (STR) genotyping. We obtained from Addgene the mouse *Ezh2* retroviral vector, MSCVhygro-F-*Ezh2* (cat. no. 24926) and the enzymatically inactive mutation vector, MSCVhygro-F-*Ezh2*-F667I (cat. no. 24927) [73], the plasmid pCS2-*Jmjd3*-F (cat. no. 17440) containing full-length mouse *Jmjd3* cDNA, and hereby generated a demethylase activity defective *Jmjd3* mutant mutating histidine 1388 to alanine (H1388A) with point mutation method [74]. SPF grade BALB/C mice and Sprague-Dawley (SD) rats were obtained from the Shanghai SLAC Laboratory Animal Co. LTD, housed and maintained in the department of Laboratory Animal Science of Shanghai Medical College Fudan University. All animals have received human care, the protocols for animal experiments were approved by the Animal Ethics Committee of Shanghai Medical College Fudan University (Permit Number: 20130227-068), and conform to the *Animal Research: Reporting of In vivo Experiments* (ARRIVE) guidelines.

Primary HSCs isolation, purification and culture

The primary HSCs were isolated from adult normal male SD rats (weighting 200-250 g) and purified using the improved method of *in situ* pronase (Sigma Aldrich, P5247)-collagenase (Sigma Aldrich, C5138) perfusion, followed by OptiPrep density gradient centrifugation according to the manufacturer protocol (Axis-shield, Norway). We determined HSCs viability by the Trypan blue exclusion test. The fresh primary HSCs were cultured in DMEM with 20% FBS in 5% CO₂ at 37°C. The detailed procedure was described in our recent work [20, 32].

Pharmacological inhibition *in vitro* and *in vivo*

We used DZNep (Selleck, S7120), GSK126 (Selleck, S7061) and GSK-J4 (Selleck, S7070) as

inhibitors of EZH2 and JMJD3 respectively, which are with DMSO (Dimethyl Sulfoxide) solvent, and used DMSO as negative control. Rat primary HSCs were treated with DZNep (1 μ M), GSK126 (5 or 10 μ M) or GSK-J4 (5 μ M). DZNep and GSK126 treatment were also conducted in JS1 and LX-2 cell lines. Experimentally diseased mice (as below) were administered with DZNep (1 mg/kg) through intraperitoneal injection twice a week. The H3K27me2/3 levels in HSCs and in liver tissue were analyzed by Western blot to ascertain the inhibitory effect.

RNA interference *in vitro* and *in vivo*

We used small interfering RNA (siRNA), short hairpin RNA (shRNA) and artificial microRNA (amiRNA) (synthesized by Shanghai HuaGene Biotech Company with sequence or target sequence listed in Table S1) to silence *Ezh2* in primary rat HSCs, mouse JS1 cells and diseased mouse liver, respectively. siRNA and shRNA specifically targeting rat or murine *Ezh2* gene, as well as their negative controls, were designed using the Sigma-Aldrich database. Rat primary HSCs were transfected with the *Ezh2* siRNA using HG-transgene reagent (Health & Gene, Ningbo, China) for the assay of lipid drop detection. The *Ezh2* shRNAs and negative control shRNA were inserted into retroviral vector pMOK.1-puro respectively, packaged into 293T Cell and then stably transfected into JS1 cells. We further utilized amiRNA-based RNAi strategy for *Ezh2* silencing *in vivo*, which shows advantages over traditional approaches by replacing the sequence of mature miRNA in its pre-miRNA stem-loop with the designed shRNA that targets specific gene of interest, thus permitting the artificial hairpin embedded in natural miRNA backbone to be processed into effective miRNA by the same cellular miRNA biogenesis machinery as natural miRNAs [32]. The amiRNA for *Ezh2* silencing was based on the structural backbone of miR-30a as loading vehicle, which is most widely used for amiRNA vector construction, and the above two valid shRNAs of *Ezh2* as targeting cargos. We thereby constructed the HSC-specific GFAP promoter-driven lentiviral amiRNA expression vectors for *Ezh2* silencing and prepared the recombinant lentivirus stock for RNAi according to the protocol described in detail in our recent work [32]. We stably transfected JS1 cells with the pLenti-amiRNAs and 48 hours later analyzed EZH2 expression with Western blot to validate the gene silencing efficiency. In experimentally diseased mice, we transduced the pLenti-amiRNA virus particles into the liver through tail-vein injection (2×10^7 infectious units/ml virus titer one time, every 5

days in one month), and analyzed the phenotypic effects on liver fibrosis in humanely sacrificed animals.

Ectopic gene expression *in vitro*

The above wild and mutant *Jmjd3* gene cDNA were cloned into adenoviral expression vector (Vigene Bioscience, China). The above wild and mutant *Ezh2* retroviral vectors were packaged into 293T cells. Rat primary HSCs and mouse JS1 cells were infected with the adenovirus containing mouse *Jmjd3* and the retrovirus containing mouse *Ezh2* respectively with the concentration of 2×10^6 infectious units/ml virus titer, and their ectopic expression in HSCs was determined by RT-qPCR and Western blot.

RT-qPCR and Western blot

The total RNAs of cells or liver tissues were extracted using TRIzol reagent (Invitrogen, 15596-026) and reversely transcribed to cDNAs using Prime Script RT reagent kit (Takara, RR037A). The transcriptional expression of genes was determined by relative quantitative PCRs using SYBR Premix Ex Tap kit (Takara, DRR420A) and was analyzed with $2^{-\Delta\Delta Ct}$ method with β -actin as inner control. The RT-qPCR primers are listed in Table S2. The total proteins of cells or liver tissue were subjected to Western blot with primary antibodies for proteins and secondary antibodies (Table S3). The relative expression of proteins was determined by gray level of target protein band, which was determined by Image J software, as compare with that of inner control β -Actin. Gene and protein expression analysis was performed in triplicate for each sample, and statistical significance was evaluated basing on three independent experiments.

Analyses of cell proliferation, cycle, apoptosis and senescence

JS1 and LX-2 cells with DZNep, GSK126 or DMSO treatment were cultured and analyzed for these cellular phenotypes. For proliferation assay: The cells were cultured in 96 well plates, each hole inoculated 2000 cells and 10 repeats were set for every treatment. In the following 1, 3 and 5 culture day, cellular activity was measured by CCK-8 kit (Dojindo, CK04-3000T), then the cell growth curve was draw according to the absorbance of cells (OD_{450}). For cell cycle and apoptosis assay: After 48 hours culture, the cells were collected, either stained with propidium iodide (PI) or double stained with Annexin-V-FITC/PI, and were subjected to flow cytometer analysis. For DNA breakage induced cellular apoptosis assay: The cells were fixed and stained by FITC-dUTP using One Step TUNEL Apoptosis Assay kit (Beyotime Biotechnology, C1086), then the

apoptotic cells were detected with green fluorescence. For cellular senescence assay: After 96 hours culture, the cells were lysed, and total protein concentration of cell lysates was determined with BCA protein assay (Pierce, A53225). The senescence-associated β -galactosidase (SA- β -Gal) activity of cell lysates was measured with cellular senescence assay kit (Cell Biolabs, CBA 231). The value of each SA- β -Gal activity was standardized by its total protein concentration. Each data was measured from triple independent experiments.

Liver fibrosis *in vivo* models

We investigated the disease relevance of EZH2 in two conventional murine models of experimental liver fibrosis, carbon tetrachloride-induced toxic injury (CCl₄), bile duct ligation-induced cholestatic injury (BDL). In normal BALB/C mice (each body weighs about 20 g and five weeks old), liver fibrosis was induced by intraperitoneal injection of CCl₄ diluent (CCl₄: olive oil is 1:4; 2.5 ml/kg body weight every 3 days). Normal mice were treated with DMSO. BDL model was induced by ligating the common bile duct under surgical operation. In both models, EZH2 inhibition was accomplished by intraperitoneal injection DZNep or DMSO as control (as above). Sham-operated animals were used as control. In CCl₄ model, HSCs-specific *Ezh2* silencing *in vivo* was accomplished by the amiRNA-based RNAi (as above). After one month for CCl₄ model and 14 days for BDL model, the mice were humanely sacrificed and serum and liver samples were prepared. The serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzyme activity were measured by automatic biochemistry analyzer (Beckman Coulter). Serum concentrations of IL10 and IL11 were measured with ELISA (YuanYe Biotechnology, China, CK-E30651R and CK-E30539R).

Masson's trichrome staining, immunohistochemistry and hydroxyproline assay

The liver tissue blocks were fixed by 4% paraformaldehyde, and then embedded into paraffin blocks. The liver tissue slices of 7 μ m thick were stained using Masson's trichrome staining kit (Sigma, HT15-1KT) or subjected to immunohistochemistry. The slices were taken photos at 200 \times magnification from six random fields for each one. Collagen secretion was evaluated by the blue area of Masson trichrome staining, and α -SMA expression was calculated by the integrated optical density (IOD) of positive area of immunohistochemistry slices, both of them were analyzed with Image-pro plus soft. The liver fibrosis level was determined as the mean of six random different fields of each section. The content of

hydroxyproline in liver tissues and serum was measured by hydroxyproline assay kit according to manufacturer's protocol (Cell Biolabs, STA-675).

RNA sequencing and bioinformatics analysis

The primary rat HSCs were treated with 1 μ M DZNep (diluted with DMSO) or DMSO as negative control, each treatment was conducted three replicates. 48 hours later, cells were harvested and total RNA was isolated. RNA-seq libraries were prepared and sequenced using HiSeq3000 (Ribo Bio Co., Ltd. Guangzhou). The genes expression profiling of rat primary HSCs with or without DZNep treatment were analyzed by PolyA-seq. The raw data were trimmed, filtered and qualified using FASTX (http://hannonlab.cshl.edu/fastx_toolkit/), clean data was aligned to rat reference genome (rn5) using TopHat2. The distributions of reads on the genome were analyzed, and the locations of reads on the exon, intronic and intergenic areas were also annotated. The expression level of every gene was evaluated by RPKM method (expected number of reads per kilobase of transcript sequence per million base pairs sequenced). Then differential expression genes (DEGs) in the HSCs with or without DZNep treatment were screened by DESeq, according to the criteria of $|\log_2(\text{fold change})| > 1$ and $q\text{-value} < 0.05$. The q -value was an adjusted p -value for false discovery rate (FDR). The expression profiles of DEGs between samples were analyzed by hierarchical clustering analysis. The DEGs were analyzed by the upstream regulator analysis (URA) of Ingenuity Pathway Analysis (IPA), to predict the relevant upstream regulators that are associated with the effect of DZNep on HSCs. $\text{Log}_2(\text{fold change})$ was utilized to calculate the Z-score of each upstream regulator. Before uploading the quantified DEGs list to IPA, we replaced the positive and negative infinity values of $\text{Log}_2(\text{fold change})$ by 8 and -10 respectively. The gene symbols of the uploaded DEGs were strictly mapped to genes and gene products of rat, while interactions were allowed to extend to which has been reported in human or mouse. We only used experimentally validated and high confident predicted evidences in IPA. 28,674 of all the 49,752 RNA-seq tracking ids were with RPKM > 0 at least in one batch. We used the R package *fcros* (version: 1.6.1) to get the average of rank values (ri) associated with those 28,674 tracking ids, and used $2 \times ri - 1$ as the final rank scores in the pre-ranked gene list (*.rnk file). The pre-ranked gene list was used for Gene Set Enrichment Analysis (GSEA) through the WEB-based GENE SeT AnaLysis Toolkit (WebGestalt) [75]. Organism "rat", method "GSEA", databases "pathway" and "geneontology" were chosen, and

default parameters with top 10 *NES* results were assigned. All RNA-seq raw data for this study have been deposited in the NCBI Gene Expression Omnibus database (GSE121736).

ChIP-qPCR

The primary rat HSCs were administrated with EZH2 inhibitor DZNep, DMSO, or were infected with adenovirus recombined with mouse *Jmjd3* gene (AD-*Jmjd3*) or AD-*GFP* as control. After four days treatment, these cells were harvested and sonicated by bioruptor (Diagenode, Belgium). By using chromatin immunoprecipitation (ChIP) assay kit (Upstate, cat no. 17-371), the supernatant of sonicated cells was co-immunoprecipitated with the anti-H3K27me3 antibody (Millipore, Germany, 07-449) or the anti-H3K27me2/me3 antibody (Active Motif, China, 39535) to assess the binding of EZH2 or JMJD3 respectively, and the mouse IgG was used as negative control. The enrichment of target gene fragment in DNA precipitate was analyzed by quantitative real-time PCR, and the primers for target genes were listed in Table S4. The fold enrichments of target genes between ChIP-DNA and input-DNA were determined by ΔCt .

Statistical analysis

The data were expressed as the means \pm standard deviation of at least three independent experiments for every assay. The statistical significance was analyzed by Student's *t*-test. $P < 0.05$ were considered significant.

Supplementary Material

Supplementary figures and tables.
<http://www.thno.org/v11p0361s1.pdf>

Acknowledgements

This work was supported by the National Key Research and Development Program of China (2018YFC0910701 and 2016YFC0901903) and the National Natural Science Foundation of China (31970827, 81572404 and 31301050).

Authors' contributions

Y.J. and H.W. designed the study. Y.J., C.X., L.W. and Y.Y.Z. performed the experiments. Y.J., F.Z. and Y.Z. analyzed and interpreted the data. H.W. and Y.J. wrote the paper. J.W., C.D. and L.J. critically revised the manuscript for important intellectual content. H.W., Y.J. and F.Z. obtained funding. F.H. supervised this study.

Competing Interests

The authors have declared that no competing

interest exists.

References

- Kisseleva T. The origin of fibrogenic myofibroblasts in fibrotic liver. *Hepatology*. 2017; 65: 1039-43.
- Lua I, Li Y, Zagory JA, Wang KS, French SW, Seigny J, et al. Characterization of hepatic stellate cells, portal fibroblasts, and mesothelial cells in normal and fibrotic livers. *J Hepatol*. 2016; 64: 1137-46.
- Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nat Commun*. 2013; 4: 2823. doi: 10.1038/ncomms3823.
- Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. *Nat Rev Gastroenterol Hepatol*. 2017; 14: 397-411.
- Zhang K, Han Y, Hu Z, Zhang Z, Shao S, Yao Q, et al. SCARNA10, a nuclear-retained long non-coding RNA, promotes liver fibrosis and serves as a potential biomarker. *Theranostics*. 2019; 9: 3622-38.
- Chen X, Li HD, Bu FT, Li XF, Chen Y, Zhu S, et al. Circular RNA circFBXW4 suppresses hepatic fibrosis via targeting the miR-18b-3p/FBXW7 axis. *Theranostics*. 2020; 10: 4851-70.
- Perugorria MJ, Wilson CL, Zeybel M, Walsh M, Amin S, Robinson S, et al. Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation. *Hepatology*. 2012; 56: 1129-39.
- Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. *Gastroenterology*. 2010; 138: 705-14, 14.e1-4.
- Zhang F, Lu S, He J, Jin H, Wang F, Wu L, et al. Ligand Activation of PPARgamma by Ligustrazine Suppresses Pericyte Functions of Hepatic Stellate Cells via SMRT-Mediated Transrepression of HIF-1alpha. *Theranostics*. 2018; 8: 610-26.
- Zeybel M, Luli S, Sabater L, Hardy T, Oakley F, Leslie J, et al. A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. *Mol Ther*. 2017; 25: 218-31.
- Zhou X, Xiong C, Tolbert E, Zhao TC, Bayliss G, Zhuang S. Targeting histone methyltransferase enhancer of zeste homolog-2 inhibits renal epithelial-mesenchymal transition and attenuates renal fibrosis. *FASEB J*. 2018; 32: 5976-89.
- Mimura I, Hirakawa Y, Kanki Y, Nakaki R, Suzuki Y, Tanaka T, et al. Genome-wide analysis revealed that DZNep reduces tubulointerstitial fibrosis via down-regulation of pro-fibrotic genes. *Sci Rep*. 2018; 8: 3779. doi: 10.1038/s41598-018-22180-5.
- Zhou X, Zang X, Ponnusamy M, Masucci MV, Tolbert E, Gong R, et al. Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression. *J Am Soc Nephrol*. 2016; 27: 2092-108.
- Coward WR, Feghali-Bostwick CA, Jenkins G, Knox AJ, Pang L. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis. *FASEB J*. 2014; 28: 3183-96.
- Xiao X, Senavirathna LK, Gou X, Huang C, Liang Y, Liu L. EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis. *Physiol Rep*. 2016; 4: e12915, doi: 10.4814/phy2.
- Tsou PS, Campbell P, Amin MA, Coit P, Miller S, Fox DA, et al. Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. *Proc Natl Acad Sci U S A*. 2019; 116: 3695-702.
- McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature*. 2012; 492: 108-12.
- Song S, Zhang R, Mo B, Chen L, Liu L, Yu Y, et al. EZH2 as a novel therapeutic target for atrial fibrosis and atrial fibrillation. *J Mol Cell Cardiol*. 2019; 135: 119-33.
- Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A, et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. *Nat Med*. 2012; 18: 1369-77.
- Jiang Y, Wang S, Zhao Y, Lin C, Zhong F, Jin L, et al. Histone H3K9 demethylase JMJD1A modulates hepatic stellate cells activation and liver fibrosis by epigenetically regulating peroxisome proliferator-activated receptor gamma. *FASEB J*. 2015; 29: 1830-41.
- Dong F, Jiang S, Li J, Wang Y, Zhu L, Hu X, et al. The Histone Demethylase KDM4D Promotes Hepatic Fibrogenesis by Modulating Toll-Like Receptor 4 Signaling Pathway. *EBioMedicine*. 2019; 39: 472-83.

22. Swigut T, Wysocka J. H3K27 demethylases, at long last. *Cell*. 2007; 131: 29-32.
23. Zhang X, Liu L, Yuan X, Wei Y, Wei X. JMJD3 in the regulation of human diseases. *Protein Cell*. 2019; 10: 864-82.
24. Pediconi N, Salerno D, Lupacchini L, Angrisani A, Peruzzi G, De Smaele E, et al. EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells. *Cell Death Dis*. 2019; 10: 518. doi: 10.1038/s41419-019-1755-2.
25. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, et al. A selective jumoni H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. *Nature*. 2012; 488: 404-8.
26. Bergmann C, Brandt A, Merlevede B, Hallenberger L, Dees C, Wohlfahrt T, et al. The histone demethylase Jumoni domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. *Ann Rheum Dis*. 2018; 77: 150-8.
27. Long F, Wang Q, Yang D, Zhu M, Wang J, Zhu Y, et al. Targeting JMJD3 histone demethylase mediates cardiac fibrosis and cardiac function following myocardial infarction. *Biochem Biophys Res Commun*. 2020; 528: 671-7.
28. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. *Mol Cell Proteomics*. 2014; 13: 397-406.
29. Wang M, Gong Q, Zhang J, Chen L, Zhang Z, Lu L, et al. Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. *Sci Rep*. 2017; 7: 43446. doi: 10.1038/srep.
30. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. *Nat Med*. 2014; 20: 1394-6.
31. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J, et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. *Nature*. 1999; 401: 480-5.
32. Jiang Y, Zhao Y, He F, Wang H. Artificial MicroRNA-Mediated Tgfb2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice. *Hum Gene Ther*. 2019; 30: 179-96.
33. Wight TN. Provisional matrix: A role for versican and hyaluronan. *Matrix Biol*. 2017; 60-61: 38-56.
34. Friedman SL. Mechanisms of hepatic fibrogenesis. *Gastroenterology*. 2008; 134: 1655-69.
35. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. *Gastroenterology*. 2012; 143: 765-76.e3.
36. Wree A, McGeough MD, Inzaugarat ME, Eguchi A, Schuster S, Johnson CD, et al. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice. *Hepatology*. 2018; 67: 736-49.
37. Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. *Hepatology*. 1998; 28: 1597-606.
38. Thompson KC, Trowern A, Fowell A, Marathe M, Haycock C, Arthur MJ, et al. Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation *In vitro*. *Hepatology*. 1998; 28: 1518-24.
39. Louis H, Van Laethem JL, Wu W, Quertinmont E, Degraef C, Van den Berg K, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. *Hepatology*. 1998; 28: 1607-15.
40. Schafer S, Viswanathan S, Widjaja AA, Lim WW, Moreno-Moral A, DeLaughter DM, et al. IL-11 is a crucial determinant of cardiovascular fibrosis. *Nature*. 2017; 552: 110-5.
41. Yan X, Lin Z, Chen F, Zhao X, Chen H, Ning Y, et al. Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling. *J Biol Chem*. 2009; 284: 30097-104.
42. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med*. 2007; 13: 1324-32.
43. Tao L, Xue D, Shen D, Ma W, Zhang J, Wang X, et al. MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis. *Arch Toxicol*. 2018; 92: 2935-46.
44. Teratani T, Tomita K, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K, et al. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. *Gastroenterology*. 2012; 142: 152-64.e10.
45. Liu C, Chen X, Yang L, Kisseleva T, Brenner DA, Seki E. Transcriptional repression of the transforming growth factor beta (TGF-beta) Pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by Nuclear Factor kappaB (NF-kappaB) p50 enhances TGF-beta signaling in hepatic stellate cells. *J Biol Chem*. 2014; 289: 7082-91.
46. Martin-Mateos R, De Assuncao TM, Arab JP, Jalan-Sakrinar N, Yaqoob U, Greuter T, et al. Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-beta Dependent Hepatic Stellate Cell Activation and Liver Fibrosis. *Cell Mol Gastroenterol Hepatol*. 2019; 7: 197-209.
47. Coward WR, Brand OJ, Pasini A, Jenkins G, Knox AJ, Pang L. Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis. *Am J Respir Cell Mol Biol*. 2018; 58: 449-60.
48. Zhou X, Zang X, Guan Y, Tolbert T, Zhao TC, Bayliss G, et al. Targeting enhancer of zeste homolog 2 protects against acute kidney injury. *Cell Death Dis*. 2018; 9: 1067. doi: 10.38/s41419-018-1012-0.
49. Elias JA, Zheng T, Whiting NL, Trow TK, Merrill WW, Zitnik R, et al. IL-1 and transforming growth factor-beta regulation of fibroblast-derived IL-11. *J Immunol*. 1994; 152: 2421-9.
50. Lindahl GE, Stock CJ, Shi-Wen X, Leoni P, Sestini P, Howat SL, et al. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. *Respir Res*. 2013; 14: 80. doi: 10.1186/465-9921-14-80.
51. Fujita T, Narumiya S. Roles of hepatic stellate cells in liver inflammation: a new perspective. *Inflamm Regen*. 2016; 36: doi: 10.1186/s41232-016-0005-6.
52. Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. *Gastroenterology*. 2004; 127: 870-82.
53. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. *Gastroenterology*. 2000; 118: 655-60.
54. Guo PF, Jin J, Sun X. Influence of IL10 gene polymorphisms on the severity of liver fibrosis and susceptibility to liver cirrhosis in HBV/HCV-infected patients. *Infect Genet Evol*. 2015; 30: 89-95.
55. Cribbs A, Hookway ES, Wells G, Lindow M, Obad S, Oerum H, et al. Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. *J Biol Chem*. 2018; 293: 2422-37.
56. Zheng J, Dong P, Mao Y, Chen S, Wu X, Li G, et al. lincRNA-p21 inhibits hepatic stellate cell activation and liver fibrogenesis via p21. *FEBS J*. 2015; 282: 4810-21.
57. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, et al. Senescence of activated stellate cells limits liver fibrosis. *Cell*. 2008; 134: 657-67.
58. Korthagen NM, van Moorsel CH, Barlo NP, Kazemier KM, Ruven HJ, Grutters JC. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. *PLoS One*. 2012; 7: e30442. doi: 10.1371/journal.pone.0030442.
59. Aravintan A, Mells G, Allison M, Leathart J, Kotronen A, Yki-Jarvinen H, et al. Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. *Cell Cycle*. 2014; 13: 1489-94.
60. Hong L, Sun QF, Xu TY, Wu YH, Zhang H, Fu RQ, et al. New role and molecular mechanism of Gadd45a in hepatic fibrosis. *World J Gastroenterol*. 2016; 22: 2779-88.
61. Tanaka N, Takahashi S, Hu X, Lu Y, Fujimori N, Golla S, et al. Growth arrest and DNA damage-inducible 45alpha protects against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet. *Biochim Biophys Acta Mol Basis Dis*. 2017; 1863: 3170-82.
62. Bae MA, Rhee SD, Jung BJ, Ahn JH, Song BJ, Cheon HG. Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARgamma agonist KR62776. *Arch Pharm Res*. 2010; 33: 433-42.
63. Park KC, Park JH, Jeon JY, Kim SY, Kim JM, Lim CY, et al. A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells. *Br J Pharmacol*. 2014; 171: 4820-30.
64. Sha MQ, Zhao XL, Li L, Li LH, Li Y, Dong TG, et al. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells. *Cell Death Dis*. 2016; 7: e2486. doi: 10.1038/cddis.2016.383.
65. Zhao W, Li Q, Ayers S, Gu Y, Shi Z, Zhu Q, et al. Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PPHF20 for ubiquitination. *Cell*. 2013; 152: 1037-50.
66. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. *Genes Dev*. 2007; 21: 1050-63.
67. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. *Mol Cancer Ther*. 2009; 8: 1579-88.

68. Yan J, Li B, Lin B, Lee PT, Chung TH, Tan J, et al. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. *Blood*. 2016; 128: 948-58.
69. Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, et al. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. *EMBO J*. 2019; 38: e99599. doi: 10.15252/embj.201899599.
70. Lai J, Ge M, Shen S, Yang L, Jin T, Cao D, et al. Activation of NFKB-JMJD3 signaling promotes bladder fibrosis via boosting bladder smooth muscle cell proliferation and collagen accumulation. *Biochim Biophys Acta Mol Basis Dis*. 2019; 1865: 2403-10.
71. Byun S, Seok S, Kim YC, Zhang Y, Yau P, Iwamori N, et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. *Nat Commun*. 2020; 11: 807. doi: 10.1038/s41467-020-14384-z.
72. Kattenhorn LM, Tipper CH, Stoica L, Geraghty DS, Wright TL, Clark KR, et al. Adeno-Associated Virus Gene Therapy for Liver Disease. *Hum Gene Ther*. 2016; 27: 947-61.
73. Wang L, Jin Q, Lee JE, Su IH, Ge K. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. *Proc Natl Acad Sci U S A*. 2010; 107: 7317-22.
74. Sen GL, Webster DE, Barragan DI, Chang HY, Khavari PA. Control of differentiation in a self-renewing mammalian tissue by the histone demethylase JMJD3. *Genes Dev*. 2008; 22: 1865-70.
75. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res*. 2019; 47: W199-W205.